FDA Moves to End Warnings Linking Testosterone Therapy to Prostate Cancer and Age-Related Use

The U.S. Department of Health and Human Services (HHS), through the FDA, has initiated a sweeping overhaul of the prescribing labels for testosterone replacement therapy (TRT). Announced during Men's Health Month in June 2026, the requested changes aim to align regulatory warnings with more than a decade of accumulated clinical evidence.[1][3]

The proposed revisions target three major areas that have long restricted how doctors prescribe the hormone. First, the FDA is removing a 2015 limitation that stated the safety and effectiveness of TRT had not been established for men with "age-related hypogonadism"—a gradual decline in testosterone associated with aging rather than a specific disease or injury.[1]

Second, the agency is drastically scaling back its warnings regarding prostate cancer. Current labels broadly state that TRT should not be used in men with known or suspected prostate cancer, warning that the therapy may increase the risk of developing the disease. Under the new guidelines, TRT will only be contraindicated for men with metastatic prostate cancer.[1][2]

Finally, the FDA is revising its warnings concerning benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. While older labels cautioned that testosterone could worsen urinary symptoms, the updated guidance reflects that mild-to-moderate BPH is not aggravated by the therapy.[1]

To understand the significance of these changes, it is necessary to look back at the regulatory climate of the mid-2010s. In 2015, amid a surge in direct-to-consumer advertising for "Low T" clinics, the FDA clamped down on testosterone prescriptions.[1]

At the time, evidence of TRT's benefits for aging men was considered limited, and early, conflicting studies raised alarms about potential cardiovascular risks, including heart attacks and strokes. The FDA responded by adding the age-related limitation and a strict cardiovascular boxed warning, effectively chilling the prescription of testosterone for millions of aging men.[2]

The turning point for testosterone science arrived with the TRAVERSE trial, a massive, multi-year clinical study involving more than 5,200 men aged 45 to 80. Designed specifically to test the safety of TRT, the trial monitored men who already had a high risk of cardiovascular disease.[1]

The TRAVERSE results were definitive: researchers found no meaningful increase in the risk of major adverse cardiovascular events among men receiving testosterone compared to those on a placebo. This robust safety data prompted the FDA to remove the cardiovascular boxed warning from all TRT products in February 2025, setting the stage for this year's broader label modernization.[2]

Following the cardiovascular update, the FDA convened a special Expert Panel on Testosterone in December 2025. Urologists, endocrinologists, and sexual health experts presented decades of accumulated data, arguing that the remaining warnings regarding prostate cancer and age-related use were actively harming patient care by perpetuating outdated myths.

The most persistent of these myths was the belief that testosterone therapy fuels prostate cancer. For decades, the medical consensus held that giving testosterone to a man with early-stage prostate cancer was akin to "pouring gasoline on a fire," a theory based on mid-20th-century observations of hormone deprivation therapy.

However, modern clinical and epidemiological evidence has thoroughly dismantled that assumption. Extensive data reviews have consistently failed to show any increased incidence of prostate cancer among men receiving TRT. The prostate gland appears to have a "saturation point" for testosterone, meaning that once baseline levels are met, additional testosterone does not spur further malignant growth.[2]

By limiting the contraindication strictly to metastatic prostate cancer—where the cancer has already spread beyond the prostate—the FDA is acknowledging that localized prostate cancer or a high risk of developing the disease should no longer automatically disqualify a man from receiving symptom-relieving hormone therapy.[1][2]

A similar evidence-based reversal applies to BPH. Because the prostate relies on androgens to grow, doctors long assumed that supplementing testosterone would inevitably worsen the urinary retention and frequent urination associated with an enlarged prostate. Clinical trials have since proven that TRT does not exacerbate these symptoms in men with mild-to-moderate BPH.[1]

Despite the sweeping removal of these warnings, the FDA maintains a stance of cautious monitoring. Prostate carcinogenesis is a notoriously slow process that can unfold over decades. Because existing clinical trials may not have followed patients long enough to detect 20-year effects, the FDA continues to recommend baseline prostate screening and ongoing monitoring for all men on TRT.[1]

For the broader medical community, these label changes represent a vital step in destigmatizing men's health. By removing the "age-related" restriction, the FDA is acknowledging that symptomatic testosterone deficiency in aging men is a valid medical condition deserving of treatment, not merely a cosmetic or lifestyle issue.[3]

Ultimately, the modernization of TRT labels shifts the paradigm of men's healthcare. By replacing historical fears with rigorous, placebo-controlled evidence, regulatory agencies are empowering physicians to treat low testosterone with confidence, ensuring that millions of men can safely access therapies that improve their energy, metabolism, and quality of life.[1][3]